BHVN [NYSE]
Biohaven Pharmaceutical Holding Company Ltd.
Index- P/E- EPS (ttm)-11.85 Insider Own1.40% Shs Outstand70.33M Perf Week0.58%
Market Cap10.06B Forward P/E- EPS next Y-5.94 Insider Trans-10.50% Shs Float61.19M Perf Month30.12%
Income-790.70M PEG- EPS next Q-2.78 Inst Own91.20% Short Float8.05% Perf Quarter11.52%
Sales737.50M P/S13.64 EPS this Y-0.30% Inst Trans1.09% Short Ratio3.09 Perf Half Y29.50%
Book/sh-6.57 P/B- EPS next Y55.70% ROA-71.50% Target Price156.22 Perf Year79.26%
Cash/sh8.54 P/C16.70 EPS next 5Y- ROE141.00% 52W Range77.63 - 151.51 Perf YTD3.48%
Dividend- P/FCF- EPS past 5Y-38.00% ROI-168.90% 52W High-5.68% Beta0.90
Dividend %- Quick Ratio1.90 Sales past 5Y- Gross Margin85.70% 52W Low84.08% ATR5.82
Employees928 Current Ratio2.00 Sales Q/Q628.10% Oper. Margin-70.80% RSI (14)67.20 Volatility1.07% 4.90%
OptionableYes Debt/Eq- EPS Q/Q30.40% Profit Margin- Rel Volume0.83 Prev Close142.60
ShortableYes LT Debt/Eq- EarningsMay 11 BMO Payout- Avg Volume1.59M Price142.90
Recom2.00 SMA2019.28% SMA5022.19% SMA20014.60% Volume140,433 Change0.21%
May-11-22Downgrade SVB Leerink Outperform → Mkt Perform $150
Oct-19-21Resumed Morgan Stanley Equal-Weight $107 → $145
Aug-10-21Downgrade UBS Buy → Neutral $108 → $109
Aug-03-21Reiterated Canaccord Genuity Buy $101 → $150
Mar-11-21Initiated UBS Buy $108
Dec-15-20Initiated H.C. Wainwright Buy $121
Apr-17-20Initiated Cowen Outperform $45
Feb-10-20Downgrade Oppenheimer Outperform → Perform
Feb-06-20Initiated Mizuho Buy
Nov-22-19Initiated Wedbush Outperform
Jun-25-19Reiterated Canaccord Genuity Buy $89 → $84
May-06-19Initiated Goldman Buy $92
Apr-09-19Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-04-19Reiterated Needham Buy $48 → $56
Jul-03-18Reiterated Needham Buy $36 → $48
Jul-02-18Reiterated Needham Buy $36 → $48
Apr-05-18Downgrade Barclays Overweight → Equal Weight $30 → $25
Feb-22-18Reiterated Canaccord Genuity Buy $30 → $39
Dec-15-17Initiated Canaccord Genuity Buy $30
Oct-03-17Reiterated Needham Buy $43 → $36
May-24-22 12:25PM  
11:13AM  
09:47AM  
May-23-22 10:54AM  
07:46AM  
07:30AM  
07:15AM  
May-13-22 08:42AM  
08:10AM  
May-12-22 04:56PM  
09:11AM  
May-11-22 02:12PM  
01:16PM  
01:12PM  
May-10-22 09:00PM  
04:19PM  
04:06PM  
03:41PM  
02:26PM  
12:06PM  
12:04PM  
11:33AM  
10:06AM  
09:51AM  
08:05AM  
07:00AM  
06:56AM  
06:56AM  
06:50AM  
06:45AM  
May-09-22 07:30AM  
May-06-22 09:18AM  
May-05-22 05:35PM  
May-02-22 03:00PM  
Apr-27-22 06:45AM  
Apr-14-22 04:30PM  
07:30AM  
Apr-08-22 08:27AM  
Apr-07-22 07:30AM  
Apr-06-22 03:22PM  
07:30AM  
Apr-01-22 07:30AM  
Mar-31-22 07:30AM  
Feb-28-22 10:04AM  
Feb-25-22 04:04PM  
08:43AM  
08:25AM  
07:00AM  
06:59AM  
06:55AM  
06:50AM  
Feb-24-22 06:20PM  
Feb-22-22 07:30AM  
Feb-18-22 05:02PM  
Feb-16-22 07:30AM  
Feb-15-22 10:28AM  
Feb-14-22 09:05AM  
07:00AM  
Feb-12-22 12:00PM  
06:30AM  
Feb-10-22 05:55PM  
Feb-06-22 11:54PM  
Feb-03-22 07:30AM  
Feb-02-22 01:38PM  
Jan-29-22 11:07AM  
Jan-25-22 07:30AM  
Jan-10-22 12:01AM  
Jan-08-22 06:30AM  
Jan-06-22 07:00AM  
Jan-05-22 07:00AM  
Dec-13-21 11:38PM  
07:00AM  
Dec-11-21 09:15AM  
Dec-09-21 10:57AM  
Dec-08-21 07:38PM  
07:38PM  
07:38PM  
08:35AM  
Dec-07-21 12:16PM  
Dec-06-21 10:35AM  
08:35AM  
07:30AM  
07:29AM  
Nov-18-21 10:24AM  
07:30AM  
Nov-17-21 06:57AM  
Nov-15-21 08:00AM  
Nov-11-21 11:44AM  
07:44AM  
03:13AM  
Nov-10-21 12:53PM  
09:43AM  
Nov-09-21 04:07PM  
10:49AM  
08:55AM  
08:31AM  
08:07AM  
08:06AM  
07:46AM  
07:45AM  
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clark George C.VP, Chief Accounting OfficerMay 10Option Exercise53.762,250120,9608,265May 12 08:58 PM
Clark George C.VP, Chief Accounting OfficerMay 10Sale141.504,200594,3004,065May 12 08:58 PM
Clark George C.VP, Chief Accounting OfficerJan 19Option Exercise46.535,670263,84615,390Jan 24 06:01 AM
Clark George C.VP, Chief Accounting OfficerJan 19Sale117.019,3751,097,0036,015Jan 24 06:01 AM
Clark George C.VP, Chief Accounting OfficerJan 10Option Exercise0.001,000010,184Jan 12 09:12 PM
Stock ElyseChief Medical OfficerJan 10Option Exercise0.0093705,374Jan 12 09:10 PM
Mehta KishanDirectorJan 10Option Exercise0.001,875010,640Jan 12 09:04 PM
Coric VladChief Executive OfficerJan 07Option Exercise0.0010,000042,218Jan 07 09:16 PM
Engelhart JamesStrategic AdvisorJan 07Option Exercise0.003,250016,952Jan 07 09:17 PM
Stock ElyseChief Medical OfficerJan 07Option Exercise0.001,00004,437Jan 07 09:17 PM
Stock ElyseChief Medical OfficerJan 07Option Exercise0.003,250012,629Jan 07 09:17 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseJan 07Option Exercise0.003,750015,630Jan 07 09:16 PM
Tilton JohnChief Commercial OfficerJan 07Option Exercise0.0087505,279Jan 07 09:18 PM
Clark George C.VP, Chief Accounting OfficerJan 07Option Exercise0.001,00009,706Jan 07 09:18 PM
Gentile KimberlySVP, Clinical OperationsJan 06Option Exercise0.003,750013,453Jan 07 09:17 PM
Conway CharlesChief Scientific OfficerJan 06Option Exercise0.003,750023,935Jan 07 09:18 PM
Clark George C.VP, Chief Accounting OfficerJan 06Option Exercise0.0087509,115Jan 07 09:18 PM
Tilton JohnChief Commercial OfficerJan 06Option Exercise0.001,25004,955Jan 07 09:18 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseJan 06Option Exercise0.005,000014,110Jan 07 09:16 PM
Stock ElyseChief Medical OfficerJan 06Option Exercise0.001,25003,437Jan 07 09:17 PM
Stock ElyseChief Medical OfficerJan 06Option Exercise0.003,750011,217Jan 07 09:17 PM
Engelhart JamesStrategic AdvisorJan 06Option Exercise0.003,750015,234Jan 07 09:17 PM
Coric VladChief Executive OfficerJan 06Option Exercise0.0012,500038,072Jan 07 09:16 PM
Buten MatthewChief Financial OfficerDec 31Option Exercise0.0012,500012,500Jan 04 09:30 PM
GREGORY JULIA PDirectorDec 20Option Exercise23.6312,000283,56012,000Dec 22 09:51 PM
GREGORY JULIA PDirectorDec 20Sale125.0012,0001,500,0000Dec 22 09:51 PM
Clark George C.VP, Chief Accounting OfficerDec 20Sale123.841,915237,1548,240Dec 22 09:51 PM
Stock ElyseChief Medical OfficerDec 15Option Exercise14.0021,919306,91429,386Dec 16 09:04 PM
Stock ElyseChief Medical OfficerDec 15Sale105.4921,9192,312,1277,467Dec 16 09:04 PM
Stock ElyseChief Medical OfficerDec 14Option Exercise15.656,939108,59914,406Dec 16 09:04 PM
Stock ElyseChief Medical OfficerDec 14Sale105.026,939728,7627,467Dec 16 09:04 PM
Engelhart JamesChief Financial OfficerDec 10Option Exercise0.0035,000046,196Dec 10 08:43 PM
Engelhart JamesChief Financial OfficerDec 10Sale102.5535,0003,589,14611,196Dec 10 08:43 PM
Doogan DeclanDirectorNov 29Sale112.8024,5252,766,433870,648Dec 01 07:24 PM
Clark George C.VP, Chief Accounting OfficerNov 26Option Exercise0.005,000012,473Nov 26 04:26 PM
Tilton JohnChief Commercial OfficerNov 25Option Exercise0.001,25003,909Nov 26 04:33 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseNov 25Option Exercise0.003,000010,127Nov 26 04:32 PM
Stock ElyseChief Medical OfficerNov 25Option Exercise0.003,37509,066Nov 26 04:33 PM
Engelhart JamesChief Financial OfficerNov 25Option Exercise0.003,700012,911Nov 26 04:29 PM
Gentile KimberlySVP, Clinical OperationsNov 25Option Exercise0.003,750011,441Nov 26 04:30 PM
Coric VladChief Executive OfficerNov 25Option Exercise0.0010,950030,359Nov 26 04:28 PM
Conway CharlesChief Scientific OfficerNov 25Option Exercise0.003,000019,897Nov 26 04:26 PM
Conway CharlesChief Scientific OfficerNov 23Option Exercise36.1810,885393,79916,897Nov 26 04:26 PM
Clark George C.VP, Chief Accounting OfficerNov 23Option Exercise32.421,91562,0847,473Nov 26 04:26 PM
Doogan DeclanDirectorNov 16Option Exercise7.87559,0004,398,760932,913Nov 17 07:03 PM
Doogan DeclanDirectorNov 16Sale116.6537,7404,402,385895,173Nov 17 07:03 PM
CHILDS JOHN WDirectorNov 15Option Exercise8.46474,2004,013,4183,025,001Nov 17 07:03 PM
CHILDS JOHN WDirectorNov 10Buy122.875,000614,3422,550,801Nov 10 06:19 PM